Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse)

Andrew M Yeager, Mitsuko Shinohara, Charlotte Shinn

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We evaluated the effectiveness of administration of high-dose busulfan (BU), an alkylating agent with substantial myeloablative but negligible immunosuppressive properties, on the engraftment of congenic normal bone marrow and spleen cells (hematopoietic cell transplantation; HCT) in murine galactosylceramidase deficiency (the twitcher mouse), a model of human sphingolipid storage disease. Untreated mice died with extensive de-myelination and failure to thrive at a median age of 40 d (range, 28-47; n = 51). The life-span of twitcher mice given HCT at age 10 d after 100 mg/kg BU was significantly prolonged (median, 94 d; range, 55-140; n = 17); these animals did not develop the hindlimb paralysis seen in untreated twitchers. Histologic examination of twitcher sciatic nerves after HCT showed remyelinated areas and decreased globoid cell inclusions. Animals given HCT after conditioning with BU had both lymphoid and hematopoietic repopulation with donor cells by 90 d after HCT, as documented by presence of donor glucose phosphate isomerase-1A activity in blood, bone marrow, spleen, and lymph nodes. After BU and HCT, galactosylceramidase activity in livers and spleens of twitcher mice reached 45 and 80% of control, respectively; only modest elevations were observed in kidneys and lymph nodes. Hydrolase activity rose to 20% in the brains and exceeded control values in the sciatic nerves of transplanted twitcher mice, indicating entry of at least some donor-derived cells and/ or hydrolase across the blood-brain and blood-nerve barriers after BU and HCT. These observations suggest that, in gene-replacement therapy for human lysosomal storage diseases, administration of BU alone may be sufficient for sustained engraftment of autologous marrow cells into which the specific hydrolase gene has been inserted.

Original languageEnglish (US)
Pages (from-to)302-305
Number of pages4
JournalPediatric Research
Volume29
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Globoid Cell Leukodystrophy
Busulfan
Cell Transplantation
Galactosylceramidase
Hydrolases
Spleen
Sciatic Nerve
xylose isomerase
Sphingolipidoses
Blood-Nerve Barrier
Lymph Nodes
Bone Marrow
Lysosomal Storage Diseases
Failure to Thrive
Alkylating Agents
Immunosuppressive Agents
Hindlimb
Blood-Brain Barrier
Paralysis
Bone Marrow Cells

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse). / Yeager, Andrew M; Shinohara, Mitsuko; Shinn, Charlotte.

In: Pediatric Research, Vol. 29, No. 3, 1991, p. 302-305.

Research output: Contribution to journalArticle

@article{105b97c9ccbe4c65a3fede1174b9148a,
title = "Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse)",
abstract = "We evaluated the effectiveness of administration of high-dose busulfan (BU), an alkylating agent with substantial myeloablative but negligible immunosuppressive properties, on the engraftment of congenic normal bone marrow and spleen cells (hematopoietic cell transplantation; HCT) in murine galactosylceramidase deficiency (the twitcher mouse), a model of human sphingolipid storage disease. Untreated mice died with extensive de-myelination and failure to thrive at a median age of 40 d (range, 28-47; n = 51). The life-span of twitcher mice given HCT at age 10 d after 100 mg/kg BU was significantly prolonged (median, 94 d; range, 55-140; n = 17); these animals did not develop the hindlimb paralysis seen in untreated twitchers. Histologic examination of twitcher sciatic nerves after HCT showed remyelinated areas and decreased globoid cell inclusions. Animals given HCT after conditioning with BU had both lymphoid and hematopoietic repopulation with donor cells by 90 d after HCT, as documented by presence of donor glucose phosphate isomerase-1A activity in blood, bone marrow, spleen, and lymph nodes. After BU and HCT, galactosylceramidase activity in livers and spleens of twitcher mice reached 45 and 80{\%} of control, respectively; only modest elevations were observed in kidneys and lymph nodes. Hydrolase activity rose to 20{\%} in the brains and exceeded control values in the sciatic nerves of transplanted twitcher mice, indicating entry of at least some donor-derived cells and/ or hydrolase across the blood-brain and blood-nerve barriers after BU and HCT. These observations suggest that, in gene-replacement therapy for human lysosomal storage diseases, administration of BU alone may be sufficient for sustained engraftment of autologous marrow cells into which the specific hydrolase gene has been inserted.",
author = "Yeager, {Andrew M} and Mitsuko Shinohara and Charlotte Shinn",
year = "1991",
language = "English (US)",
volume = "29",
pages = "302--305",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hematopoietic cell transplantation after administration of high-dose busulfan in murine globoid cell leukodystrophy (the twitcher mouse)

AU - Yeager, Andrew M

AU - Shinohara, Mitsuko

AU - Shinn, Charlotte

PY - 1991

Y1 - 1991

N2 - We evaluated the effectiveness of administration of high-dose busulfan (BU), an alkylating agent with substantial myeloablative but negligible immunosuppressive properties, on the engraftment of congenic normal bone marrow and spleen cells (hematopoietic cell transplantation; HCT) in murine galactosylceramidase deficiency (the twitcher mouse), a model of human sphingolipid storage disease. Untreated mice died with extensive de-myelination and failure to thrive at a median age of 40 d (range, 28-47; n = 51). The life-span of twitcher mice given HCT at age 10 d after 100 mg/kg BU was significantly prolonged (median, 94 d; range, 55-140; n = 17); these animals did not develop the hindlimb paralysis seen in untreated twitchers. Histologic examination of twitcher sciatic nerves after HCT showed remyelinated areas and decreased globoid cell inclusions. Animals given HCT after conditioning with BU had both lymphoid and hematopoietic repopulation with donor cells by 90 d after HCT, as documented by presence of donor glucose phosphate isomerase-1A activity in blood, bone marrow, spleen, and lymph nodes. After BU and HCT, galactosylceramidase activity in livers and spleens of twitcher mice reached 45 and 80% of control, respectively; only modest elevations were observed in kidneys and lymph nodes. Hydrolase activity rose to 20% in the brains and exceeded control values in the sciatic nerves of transplanted twitcher mice, indicating entry of at least some donor-derived cells and/ or hydrolase across the blood-brain and blood-nerve barriers after BU and HCT. These observations suggest that, in gene-replacement therapy for human lysosomal storage diseases, administration of BU alone may be sufficient for sustained engraftment of autologous marrow cells into which the specific hydrolase gene has been inserted.

AB - We evaluated the effectiveness of administration of high-dose busulfan (BU), an alkylating agent with substantial myeloablative but negligible immunosuppressive properties, on the engraftment of congenic normal bone marrow and spleen cells (hematopoietic cell transplantation; HCT) in murine galactosylceramidase deficiency (the twitcher mouse), a model of human sphingolipid storage disease. Untreated mice died with extensive de-myelination and failure to thrive at a median age of 40 d (range, 28-47; n = 51). The life-span of twitcher mice given HCT at age 10 d after 100 mg/kg BU was significantly prolonged (median, 94 d; range, 55-140; n = 17); these animals did not develop the hindlimb paralysis seen in untreated twitchers. Histologic examination of twitcher sciatic nerves after HCT showed remyelinated areas and decreased globoid cell inclusions. Animals given HCT after conditioning with BU had both lymphoid and hematopoietic repopulation with donor cells by 90 d after HCT, as documented by presence of donor glucose phosphate isomerase-1A activity in blood, bone marrow, spleen, and lymph nodes. After BU and HCT, galactosylceramidase activity in livers and spleens of twitcher mice reached 45 and 80% of control, respectively; only modest elevations were observed in kidneys and lymph nodes. Hydrolase activity rose to 20% in the brains and exceeded control values in the sciatic nerves of transplanted twitcher mice, indicating entry of at least some donor-derived cells and/ or hydrolase across the blood-brain and blood-nerve barriers after BU and HCT. These observations suggest that, in gene-replacement therapy for human lysosomal storage diseases, administration of BU alone may be sufficient for sustained engraftment of autologous marrow cells into which the specific hydrolase gene has been inserted.

UR - http://www.scopus.com/inward/record.url?scp=0026020307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026020307&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 302

EP - 305

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 3

ER -